Investors Purchase Large Volume of TransMedics Group Put Options (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) saw unusually large options trading on Friday. Stock traders bought 17,429 put options on the company. This represents an increase of 493% compared to the average volume of 2,937 put options.

TransMedics Group Stock Performance

TransMedics Group stock traded up $0.93 during midday trading on Friday, reaching $84.83. The stock had a trading volume of 347,883 shares, compared to its average volume of 1,018,254. The firm has a market capitalization of $2.93 billion, a PE ratio of 21.84, a P/E/G ratio of 1.21 and a beta of 1.90. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The firm’s 50-day moving average price is $84.46 and its 200 day moving average price is $86.88.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same period last year, the firm earned $0.92 EPS. As a group, research analysts predict that TransMedics Group will post 1.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. TD Cowen reissued a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Stifel Nicolaus raised their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, June 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Finally, UBS Group dropped their price objective on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $121.10.

Insider Activity at TransMedics Group

In related news, Director David Weill purchased 1,336 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average cost of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director owned 16,392 shares of the company’s stock, valued at $1,338,078.96. This represents a 8.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 6.90% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Candriam S.C.A. raised its holdings in shares of TransMedics Group by 45.4% in the 1st quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock valued at $15,783,000 after acquiring an additional 49,580 shares in the last quarter. Emerald Investment Advisers LLC purchased a new position in shares of TransMedics Group during the second quarter worth about $2,023,000. Deutsche Bank AG purchased a new position in shares of TransMedics Group during the second quarter worth about $14,415,000. Regency Capital Management Inc. DE bought a new stake in TransMedics Group during the first quarter valued at approximately $2,172,000. Finally, Headlands Technologies LLC bought a new stake in TransMedics Group during the second quarter valued at approximately $1,634,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.